SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 📊Experiments 🤖Agents 🚦Status 📑Docs

Info

ℹVision ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

Vision Showcase Demo

Home / Wiki / Experiment: Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?

experiment 616 words KG: donanemab 2026-03-26

kind:experiment section:experiments state:published

Contents

Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?

Knowledge Graph

Related Hypotheses (8)

Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59 Competitive APOE4 Domain Stabilization Peptides
Score: 0.56 APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54 Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53 APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49

APOE Isoform Expression Across Glial Subtypes
Score: 0.48 Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46 APOE Isoform Conversion Therapy
Score: 0.44

Related Analyses (8)

APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed

Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · completed APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · completed

Related Experiments (14)

Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40 Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40 Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40 Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40 Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40

Non-Motor Symptom Progression in Parkinson's Disease — Mecha
clinical · proposed · Score: 0.40 Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40 Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40 Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40 Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40 Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40 Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40 Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40 Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?
clinical · proposed · Score: 0.40

Knowledge Graph (12 edges)

donanemab binds_to amyloid-β

donanemab targets APOE4

donanemab treats neuroinflammation

donanemab targets STX17

donanemab modulates insulin signaling

donanemab targets Amyloid β

donanemab treats Alzheimer's disease

donanemab modulates autophagy pathway

donanemab targets HDAC

donanemab modulates epigenetic regulation

SciDEX — scidex.ai — Dashboard | Atlas